Sierra Oncology, Inc.
CHK1 (SRA737)/PARPI COMBINATION METHODS OF INHIBITING TUMOR GROWTH

Last updated:

Abstract:

Herein disclosed are combinations of Checkpoint Kinase 1 (Chk1) inhibitors and PARP inhibitors useful for inhibiting the growth of tumors such as those in patients with cancer. In particular, the combination demonstrates remarkable synergistic effects on cancer cells that are representative models for tumors. Also provided for are methods for treating disorders or diseases mediated or affected by Chk1 and/or PARP activity.

Status:
Application
Type:

Utility

Filling date:

10 Apr 2018

Issue date:

18 Mar 2021